vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and Paymentus Holdings, Inc. (PAY). Click either name above to swap in a different company.
Paymentus Holdings, Inc. is the larger business by last-quarter revenue ($330.5M vs $183.1M, roughly 1.8× Amphastar Pharmaceuticals, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs 6.3%, a 7.1% gap on every dollar of revenue. On growth, Paymentus Holdings, Inc. posted the faster year-over-year revenue change (28.1% vs -1.8%). Paymentus Holdings, Inc. produced more free cash flow last quarter ($45.0M vs $24.6M). Over the past eight quarters, Paymentus Holdings, Inc.'s revenue compounded faster (33.7% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Paymentus Holdings, Inc. is a leading cloud-based bill payment and customer engagement technology provider. It offers integrated digital payment solutions, billing automation tools, and self-service portals for enterprises across utilities, financial services, government, healthcare, and telecommunications segments, primarily operating in the North American market.
AMPH vs PAY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $330.5M |
| Net Profit | $24.4M | $20.7M |
| Gross Margin | 46.8% | 25.4% |
| Operating Margin | 19.4% | 7.3% |
| Net Margin | 13.3% | 6.3% |
| Revenue YoY | -1.8% | 28.1% |
| Net Profit YoY | -35.7% | 57.2% |
| EPS (diluted) | $0.51 | $0.16 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $330.5M | ||
| Q3 25 | $191.8M | $310.7M | ||
| Q2 25 | $174.4M | $280.1M | ||
| Q1 25 | $170.5M | $275.2M | ||
| Q4 24 | $186.5M | $257.9M | ||
| Q3 24 | $191.2M | $231.6M | ||
| Q2 24 | $182.4M | $197.4M | ||
| Q1 24 | $171.8M | $184.9M |
| Q4 25 | $24.4M | $20.7M | ||
| Q3 25 | $17.4M | $17.7M | ||
| Q2 25 | $31.0M | $14.7M | ||
| Q1 25 | $25.3M | $13.8M | ||
| Q4 24 | $38.0M | $13.1M | ||
| Q3 24 | $40.4M | $14.4M | ||
| Q2 24 | $37.9M | $9.4M | ||
| Q1 24 | $43.2M | $7.2M |
| Q4 25 | 46.8% | 25.4% | ||
| Q3 25 | 51.4% | 24.1% | ||
| Q2 25 | 49.6% | 25.5% | ||
| Q1 25 | 50.0% | 24.0% | ||
| Q4 24 | 46.5% | 25.6% | ||
| Q3 24 | 53.3% | 26.2% | ||
| Q2 24 | 52.2% | 29.8% | ||
| Q1 24 | 52.4% | 28.5% |
| Q4 25 | 19.4% | 7.3% | ||
| Q3 25 | 13.2% | 6.4% | ||
| Q2 25 | 24.2% | 5.7% | ||
| Q1 25 | 21.9% | 5.7% | ||
| Q4 24 | 24.2% | 5.5% | ||
| Q3 24 | 29.8% | 5.2% | ||
| Q2 24 | 30.3% | 5.2% | ||
| Q1 24 | 27.9% | 4.5% |
| Q4 25 | 13.3% | 6.3% | ||
| Q3 25 | 9.0% | 5.7% | ||
| Q2 25 | 17.8% | 5.3% | ||
| Q1 25 | 14.8% | 5.0% | ||
| Q4 24 | 20.4% | 5.1% | ||
| Q3 24 | 21.1% | 6.2% | ||
| Q2 24 | 20.8% | 4.7% | ||
| Q1 24 | 25.1% | 3.9% |
| Q4 25 | $0.51 | $0.16 | ||
| Q3 25 | $0.37 | $0.14 | ||
| Q2 25 | $0.64 | $0.11 | ||
| Q1 25 | $0.51 | $0.11 | ||
| Q4 24 | $0.74 | $0.11 | ||
| Q3 24 | $0.78 | $0.11 | ||
| Q2 24 | $0.73 | $0.07 | ||
| Q1 24 | $0.81 | $0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $320.9M |
| Total DebtLower is stronger | $608.7M | — |
| Stockholders' EquityBook value | $788.8M | $560.4M |
| Total Assets | $1.6B | $667.9M |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $320.9M | ||
| Q3 25 | $276.2M | $287.9M | ||
| Q2 25 | $231.8M | $266.4M | ||
| Q1 25 | $236.9M | $245.8M | ||
| Q4 24 | $221.6M | $205.9M | ||
| Q3 24 | $250.5M | $187.5M | ||
| Q2 24 | $217.8M | $188.8M | ||
| Q1 24 | $289.6M | $180.1M |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $560.4M | ||
| Q3 25 | $776.7M | $537.4M | ||
| Q2 25 | $757.5M | $516.7M | ||
| Q1 25 | $751.3M | $500.4M | ||
| Q4 24 | $732.3M | $485.6M | ||
| Q3 24 | $727.7M | $468.8M | ||
| Q2 24 | $713.3M | $451.6M | ||
| Q1 24 | $672.4M | $439.4M |
| Q4 25 | $1.6B | $667.9M | ||
| Q3 25 | $1.7B | $644.4M | ||
| Q2 25 | $1.6B | $609.5M | ||
| Q1 25 | $1.6B | $590.9M | ||
| Q4 24 | $1.6B | $576.2M | ||
| Q3 24 | $1.5B | $552.9M | ||
| Q2 24 | $1.5B | $527.7M | ||
| Q1 24 | $1.6B | $514.0M |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $45.1M |
| Free Cash FlowOCF − Capex | $24.6M | $45.0M |
| FCF MarginFCF / Revenue | 13.4% | 13.6% |
| Capex IntensityCapex / Revenue | 4.5% | 0.0% |
| Cash ConversionOCF / Net Profit | 1.35× | 2.18× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $161.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $45.1M | ||
| Q3 25 | $52.6M | $35.1M | ||
| Q2 25 | $35.6M | $31.5M | ||
| Q1 25 | $35.1M | $50.4M | ||
| Q4 24 | $29.0M | $27.9M | ||
| Q3 24 | $60.0M | $6.7M | ||
| Q2 24 | $69.1M | $18.0M | ||
| Q1 24 | $55.3M | $11.0M |
| Q4 25 | $24.6M | $45.0M | ||
| Q3 25 | $47.2M | $35.0M | ||
| Q2 25 | $25.0M | $31.4M | ||
| Q1 25 | $24.4M | $50.4M | ||
| Q4 24 | $16.6M | $27.8M | ||
| Q3 24 | $46.2M | $6.7M | ||
| Q2 24 | $63.1M | $17.8M | ||
| Q1 24 | $46.5M | $10.8M |
| Q4 25 | 13.4% | 13.6% | ||
| Q3 25 | 24.6% | 11.3% | ||
| Q2 25 | 14.3% | 11.2% | ||
| Q1 25 | 14.3% | 18.3% | ||
| Q4 24 | 8.9% | 10.8% | ||
| Q3 24 | 24.1% | 2.9% | ||
| Q2 24 | 34.6% | 9.0% | ||
| Q1 24 | 27.1% | 5.9% |
| Q4 25 | 4.5% | 0.0% | ||
| Q3 25 | 2.8% | 0.0% | ||
| Q2 25 | 6.1% | 0.0% | ||
| Q1 25 | 6.3% | 0.0% | ||
| Q4 24 | 6.7% | 0.0% | ||
| Q3 24 | 7.2% | 0.0% | ||
| Q2 24 | 3.3% | 0.1% | ||
| Q1 24 | 5.1% | 0.1% |
| Q4 25 | 1.35× | 2.18× | ||
| Q3 25 | 3.03× | 1.98× | ||
| Q2 25 | 1.15× | 2.14× | ||
| Q1 25 | 1.39× | 3.65× | ||
| Q4 24 | 0.76× | 2.12× | ||
| Q3 24 | 1.48× | 0.47× | ||
| Q2 24 | 1.82× | 1.93× | ||
| Q1 24 | 1.28× | 1.52× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
PAY
| Payment Transaction Processing Revenue | $326.9M | 99% |
| Other | $3.5M | 1% |
